Alembic Limited began in 1907 as a pharmaceutical manufacturer, but over more than a century the land under its Vadodara factories became more valuable than the factories themselves. Today the company is a hybrid: a niche real-estate developer turning its legacy industrial campus into a mixed-use urban destination called Alembic City, while running a legacy active-pharmaceutical-ingredient (API) business that management itself calls “barely sustainable”. The recurring approach is simple - unlock the hidden worth of prime city-centre land that the company already owns, and use the cash from property to manage the decline of a manufacturing past.
Business segments
Two businesses at opposite ends of their lifecycles - a real-estate engine built on repurposed industrial land, and a legacy pharmaceutical operation being right-sized - each a product of the same Vadodara campus.
1. Real estate: transforming a factory campus into a city
Alembic City is a branded, mixed-use urban campus on the company’s own former industrial land, where the company sells premium homes and leases commercial space with no land-acquisition cost.
- Land already owned, not bought - the entire real-estate business sits on the company’s legacy industrial land bank in central Vadodara, so the developer avoids the single largest cost that rivals face when starting a project.
- Homes sold to Gujarat’s upwardly mobile - residential projects like VEDA-II (which includes the tallest residential tower in Vadodara) and Townhouse24 (which sold out completely during FY25) target salaried professionals, entrepreneurs, high-net-worth individuals and non-resident Indians.
- Commercial leases build a recurring-income stream - the company develops office buildings for long-term rental, and during FY25 a new commercial building had more than half its leasable area pre-leased to marquee corporate clients before completion.
- A campus designed as a destination, not just buildings - the Alembic City campus and Alembic Art District combine high-street retail, food courts, restaurants and entertainment zones at a human scale, with continuous upgrades to roads, landscaping and infrastructure to keep the area a city-centre draw.
- Construction kept local and self-reliant - more than half of key materials are sourced within a 200-kilometre radius, and steel is cut, bent and fabricated on site to avoid supply-chain dependencies.
2. Bulk drugs (API manufacturing): a legacy operation in managed decline
A small-scale, job-work-driven pharmaceutical operation that produces generic active ingredients, but its city-centre location and thin margins make renewal uneconomic.
- Makes ingredients for other drug companies - the business produces APIs and intermediates such as Estolate, Fluoxetine and Venlafaxine, mostly on a job-work basis for domestic pharmaceutical customers rather than selling branded products of its own.
- The factory is in the wrong place - the manufacturing plant sits on Alembic Road in the heart of Vadodara, where the land is now far more valuable for real estate; management says committing capital to modernise the facility is “economically unviable”.
- A shrinking, low-margin portfolio - the business faces declining selling prices for its proprietary molecules, falling volumes in job-work, a narrow customer base, and competition from small local players and cheaper imports.
- Infrastructure is fragile - during FY25 the operation suffered a complete breakdown of its gas engine, a critical utility component, while it relies on a patchwork of captive windmills, diesel generators and bore wells alongside grid power.
- Being deliberately right-sized, not grown - the company has already reduced the footprint of manufacturing areas that have no utilisation and plans to repurpose the vacated space for other business uses.
Group structure and partners
Alembic Limited sits inside a web of related entities - a holding company, a wholly-owned leasing subsidiary, a significant stake in a listed pharma associate, and deep operational ties with a sister real-estate firm.
- Held by Nirayu Limited - the company’s parent is Nirayu Limited, and its shares are listed on the BSE and NSE in India.
- A subsidiary dedicated to commercial leasing - Alembic City Limited is a wholly-owned subsidiary that handles the leasing of commercial properties, separating that recurring-income stream from the development business.
- A 28.54% stake in Alembic Pharmaceuticals - the company holds a significant minority interest in its listed associate, Alembic Pharmaceuticals Limited, with which it also has an ongoing framework for supplying goods, doing job work and leasing premises worth up to ₹65 crore a year.
- Shreno Limited is the closest operating partner - the two companies buy, sell and lease property to each other, transfer development rights and FSI (floor space index), jointly develop projects on revenue- or area-sharing bases, and provide loans and guarantees, under a framework capped at ₹30 crore per annum, plus a separate one-time FSI-utilisation arrangement with a base consideration of ₹65.45 crore.